SHINE Secures European Marketing Authorization for Ilumira, Latest Step in Building Integrated Nuclear Medicine Platform

European approval opens a major new market for SHINE's non-carrier-added Lu-177 as the company builds an integrated, U.S.-based platform spanning diagnostic and therapeutic radioisotopes JANESVILLE, Wis., May 29, 2026 /PRNewswire/ -- SHINE Technologies, a fusion company commercializing in...